Sign In
Buy ERAS
$13.67
-0.310 (-2.22%)
At Close: Jun 18, 2026
Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022
08:00am, Monday, 26'th Sep 2022
SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for
Erasca to Present at the Morgan Stanley Global Healthcare Conference
08:31am, Friday, 09'th Sep 2022
SAN DIEGO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for
Here's Why Erasca, Inc. (ERAS) Looks Ripe for Bottom Fishing
11:18am, Tuesday, 23'rd Aug 2022
Erasca, Inc. (ERAS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean
Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 362%: Here's is How to Trade
11:17am, Thursday, 09'th Jun 2022
The consensus price target hints at a 361.8% upside potential for Erasca, Inc. (ERAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est
Erasca to Present at the 2022 Jefferies Healthcare Conference
09:00am, Friday, 03'rd Jun 2022
SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
Eli Lilly, Erasca ink clinical trial/supply agreement
02:25pm, Thursday, 10'th Mar 2022 Seeking Alpha
Erasca (ERAS) entered a clinical trial collaboration and supply agreement with Eli Lilly (LLY) for cetuximab (ERBITUX)
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination
01:00pm, Thursday, 10'th Mar 2022 GlobeNewswire
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated clinically in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant mCRC
Erasca (ERAS) Investor Presentation - Slideshow
02:40pm, Saturday, 12'th Feb 2022 Seeking AlphaIs a Surprise Coming for Erasca (ERAS) This Earnings Season?
10:45am, Tuesday, 08'th Feb 2022
Erasca (ERAS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day
08:00am, Thursday, 03'rd Feb 2022
SAN DIEGO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p
Erasca (NASDAQ:ERAS) Shares Gap Up to $13.65
03:30pm, Friday, 17'th Dec 2021 Transcript Daily
Erasca Inc (NASDAQ:ERAS)s share price gapped up prior to trading on Friday . The stock had previously closed at $13.65, but opened at $14.32. Erasca shares last traded at $14.47, with a volume of 111 shares. Separately, Zacks Investment Research lowered Erasca from a hold rating to a sell rating in a research note on []
Erasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme and Collaboration with GCAR for Potential Inclusion in GBM AGILE Clinical Trial
01:00pm, Friday, 17'th Dec 2021 Intrado Digital Media
IND filing achieved ahead of schedule; dosing of first patient in THUNDERBBOLT-1 Phase 1 clinical trial in recurrent GBM anticipated in Q1 2022
Erasca (NASDAQ:ERAS) Shares Down 6.9%
05:32pm, Tuesday, 14'th Dec 2021 Dakota Financial News
Erasca Inc (NASDAQ:ERAS)s share price fell 6.9% during trading on Tuesday . The stock traded as low as $12.96 and last traded at $13.03. 2,498 shares traded hands during trading, a decline of 99% from the average session volume of 365,669 shares. The stock had previously closed at $14.00. Separately, Zacks Investment Research cut Erasca []
Erasca Added to the Nasdaq Biotechnology Index
01:00pm, Tuesday, 14'th Dec 2021 Intrado Digital Media
SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.
